Introduction
============

The secondary metabolic process in *Streptomyces* is regulated by a complex regulatory network involving pathway-specific, pleiotropic, and global regulators which respond to a variety of physiological and environmental condition alterations ([@B36]; [@B17]). The best characterized is the A-factor regulatory cascade in which AdpA is the most important transcriptional factor for the secondary metabolism ([@B12]; [@B26]). In early culture stages, the transcription of *adpA* in *Streptomyces griseus* is repressed by ArpA, the receptor protein for A-factor ([@B27]). When A-factor reaches a critical concentration, it binds to ArpA and confers the conformational change of ArpA ([@B25]). This results in dissociation of ArpA from the *adpA* promoter, in turn switching on the expression of *adpA* ([@B25]). The induced AdpA then activates the transcription of various genes related to secondary metabolism such as *strR*, the pathway-specific regulatory genes for streptomycin in *S. griseus* ([@B29]; [@B35]).

AdpA is a member of the AraC/XylS family proteins ([@B7]). It has been suggested to form a dimer through the N-terminal portion which belong to the ThiJ/PfpI/DJ-1 family ([@B38]; [@B26]). To date, a number of AdpA orthologs have been described as having essential roles in the secondary metabolism in many *Streptomyces* species, such as *Streptomyces lividans* ([@B9]), *Streptomyces coelicolor* A3(2) ([@B33]; [@B24]), *Streptomyces ansochromogenes* ([@B28]), *Streptomyces avermitilis* ([@B16]), *Streptomyces hygroscopicus* 5008 ([@B34]), and *Streptomyces clavuligerus* ([@B18]).

Typically, AdpA is regarded as an activator for downstream regulated genes, except itself which is proved to be negatively auto-regulated by binding to its own promoter region ([@B14]; [@B10]). The molecular mechanism of transcriptional activation begins as a dimer of AdpA binds to the target sites with consensus sequences which then recruit RNA polymerase to the promoter for transcriptional initiation ([@B38]; [@B13]). For different target genes, AdpA showed a different number of binding sites in the promoter regions. For example, there are two AdpA-binding sites in the promoter of *strR* ([@B35]), whereas there are three AdpA-binding sites for regulation of *ssgA* ([@B37]). However, the precise regulation mechanism how the AdpA binds to multiple sites to activate transcription has not been experimentally determined. Based on the importance of AdpA in the biosynthesis of the secondary metabolism, it is necessary to elucidate details of its regulatory mechanisms.

Natamycin, an antifungal polyene macrolide antibiotic, is synthesized by a type I polyketide synthase gene cluster. Previous analysis of the gene cluster of natamycin in *Streptomyces chattanoogensis* L10 revealed the existence of 17 open-reading frames, including two pathway-specific genes, *scnRI* and *scnRII* ([@B5]). These two genes showed high sequence identity to *pimR* and *pimM* of *Streptomyces natalensis*, respectively ([@B1]; [@B30]). Gene disruption of *scnRI* resulted in a large decrease in the expression of biosynthetic genes, indicating its role as a pivotal activator for the biosynthesis of natamycin ([@B5]). *scnRII*, adjacent but divergently transcribed transcriptional regulatory genes, was shown to act as a second positive regulator for natamycin production ([@B4]). We also had proved that AdpA~ch~ controls the production of natamycin, but the detailed relationship among AdpA~ch~, ScnRI, and ScnRII had not been well characterized ([@B5]).

Here, we reveal the sophisticated regulatory characteristics of AdpA~ch~ in the natamycin biosynthesis of *S. chattanoogensis* L10. AdpA~ch~ acts as a "higher level" pleiotropic regulator for transcription of the two divergently transcribed pathway-specific genes, *scnRI* and *scnRII*. In this regulatory process, AdpA~ch~ shows a bi-stable regulatory ability, where it firstly acts as an activator, then a repressor. Moreover, natamycin production was enhanced by mutating the AdpA~ch~-binding sites which had an inhibitory effect. This work not only advances the understanding of detailed regulatory mechanism of AdpA, but also provides a potential target for the enhancement of other antibiotic production levels by manipulating the regulatory network.

Results
=======

AdpA~ch~ Identified as a "Higher Level" Pleiotropic Regulator for Natamycin Biosynthesis
----------------------------------------------------------------------------------------

In our previous study, the biosynthetic gene cluster of natamycin has been cloned and characterized in *S. chattanoogensis* L10. Within this there are two divergently transcribed genes, *scnRI* and *scnRII*, encoding proteins that resemble pathway-specific regulators ([@B4], [@B5]). Although the functions of these two regulators have been well characterized, an important question remains as to whether there are multiple levels of control in the biosynthesis of natamycin. Based on our previous study that AdpA~ch~ affected the transcription of these two pathway-specific genes ([@B5]), we speculated that AdpA~ch~ may act as a "higher level" pleiotropic regulator for regulating the natamycin biosynthesis.

To test this hypothesis, electrophoretic mobility shift assays (EMSAs) were applied. As shown in **Figure [1](#F1){ref-type="fig"}**, retardation was readily detected upon the addition of 50 pM AdpA~ch~ with the probe RI--RII, while the addition of 50- to 100-fold excess of unlabeled specific PCR product reduced the proportion of the labeled promoter-containing fragment (**Figure [1](#F1){ref-type="fig"}**). These data clearly demonstrate that AdpA~ch~ could specifically bind to the *scnRI*--*scnRII* intergenic region and could control the expression of these two pathway-specific genes.

![AdpA~ch~ binds to the DNA sequence of the intergenic promoter region between *scnRI* and *scnRII*. Lanes 1--3, DNA probe with AdpA~ch~ protein 0, 50, and 100 pM, respectively. Lanes 4 and 5, 50- and 100-fold excess of unlabeled specific PCR product was added into binding reactions.](fmicb-09-00316-g001){#F1}

DNase I Footprinting Assay Reveals Six AdpA~ch~-Binding Sites in the *scnRI*--*scnRII* Intergenic Region
--------------------------------------------------------------------------------------------------------

To identify the exact DNA sequences that AdpA~ch~ protected in the *scnRI*--*scnRII* intergenic region, DNase I footprinting assays, in absence or presence of purified recombinant AdpA~ch~, were performed. In our previous studies, we had determined the transcription start site (TSS) of the two pathway-specific genes, *scnRI* and *scnRII* ([@B5]). As seen in **Figure [2A](#F2){ref-type="fig"}**, at a lower AdpA~ch~ protein concentration of 100 pM, the DNA strands of the *scnRI*--*scnRII* intergenic region showed two protected regions, Site C and Site D, extending from positions -69 to -44 and -106 to -74 relative to the TSS of *scnRI*. When increasing the protein concentration to 500 pM, another four protected regions (Sites A, B, E, and F) were observed. With respect to the *scnRI* TSS, the AdpA~ch~-binding Site A locates at positions +8 to +54, Site B at positions -20 to +2, Site E at positions -161 to -114, and Site F at positions -283 to -259 (**Figure [2B](#F2){ref-type="fig"}**). The six AdpA~ch~-binding sites were spread over the *scnRI*--*scnRII* intergenic region. Notably, Site A was located downstream of the *scnRI* TSS, while Site B overlapped the -10 region of the *scnRI* promoter. Site F was located downstream of the *scnRII* TSS, and Site E overlapped the -35 region of the *scnRII* promoter. This data suggest that AdpA~ch~ might have a negative regulatory ability for the expression of these two pathway-specific genes. Additionally, the results from the DNase I footprinting assay also reveal that AdpA~ch~ may have higher affinity to Site C and Site D than to the others.

![DNase I footprinting assay for determination of the AdpA~ch~-binding sites. **(A)** A 5′-FAM-labeled probe p*RI-RII* was used in the DNase I footprinting assay with 0, 100, and 500 pM purified AdpA~ch~, respectively. The protected regions are underlined. **(B)** Nucleotide sequences of the *scnRI*--*scnRII* intergenic region showing the predicted AdpA~ch~-binding sites. The TSS is marked by a bent arrow, the AdpA~ch~-binding sites are underlined, and the --10 and --35 regions are overlined.](fmicb-09-00316-g002){#F2}

The Consensus AdpA~ch~-Binding Sequence in the AdpA~ch~-Binding Sites
---------------------------------------------------------------------

The orthologs of AdpA~ch~ identified in *S. griseus* and *S. coelicolor* have been reported to have the consensus binding sequence, 5-TGGCSNGWWY-3 (S: G or C; W: A or T; Y: T or C; N: any nucleotide) ([@B38]). After alignment of these six protected regions, we also found that there were highly conserved AdpA~ch~-binding sequences in each binding site (**Figure [3A](#F3){ref-type="fig"}**). To further study the roles of these consensus sequences in the AdpA~ch~-binding ability, EMSAs were carried out using the probes containing either the sequences of wild-type (wt) binding sites or the mutated sites (**Figure [3A](#F3){ref-type="fig"}**). As shown in **Figure [3B](#F3){ref-type="fig"}**, no binding shift was detected for the mutated sites A--F when compared with their corresponding wt targets. Taken together, these data demonstrated that AdpA~ch~ indeed has six binding sites in the *scnRI*--*scnRII* intergenic region and the consensus sequence is essential for the binding activity of AdpA~ch~.

![Mutational analysis of the AdpA~ch~-binding sites. **(A)** Mutations introduced in the six putative AdpA~ch~-binding sites. The predicted AdpA~ch~-binding consensus sequences are in bold, and these consensus sequences are changed with an *EcoRI* site indicated with underlines. **(B)** EMSAs for determination of AdpA~ch~ binding to mutated sequences. Probes A--F contained the fragment of Sites A--F as shown in **A**, respectively. Probes mA--mF contained the fragment of corresponding mutated sites. The amounts of AdpA~ch~ protein used were 50 and 100 pM.](fmicb-09-00316-g003){#F3}

AdpA~ch~ Has Differing Affinities for Different Binding Sites
-------------------------------------------------------------

In the DNase I footprinting analysis, Site C and Site D were occupied with a lower concentration of AdpA~ch~ than the other sites. This suggests that there may be affinity differences for AdpA~ch~ between the six binding sites. To test this possibility, competitive EMSAs with 50- to 100-fold excess of unlabeled fragments of six AdpA~ch~-binding sites were used to compete with each labeled fragment. As shown in **Figure [4A](#F4){ref-type="fig"}**, 100-fold excess of unlabeled S~B~′ (Site B) and S~F~′ (Site F) could not completely abolish AdpA~ch~ complex formation with the labeled probe S~A~ (Site A). However, the same amount of unlabeled S~C~′ (Site C), S~D~′ (Site D), and S~E~′ (Site E) outcompeted the labeled probe S~A~. This result indicated that AdpA~ch~ binds to Site A more tightly than Site B and Site F, but less tightly than Site C, Site D, and Site E. Following this way, we could conclude that Site B has less affinity for AdpA~ch~ than others, except for Site F (**Figure [4B](#F4){ref-type="fig"}**), which was the weakest affinity among the six binding sites (**Figure [4F](#F4){ref-type="fig"}**), and Site D was the strongest affinity of these six sites (**Figure [4D](#F4){ref-type="fig"}**). The affinity of Site E for AdpA~ch~ was between that of Site C and Site A (**Figures [4A,C,E](#F4){ref-type="fig"}**). Therefore, we determined the affinity of AdpA~ch~ to different binding sites in the following order: Site D \> Site C \> Site E \> Site A \> Site B \> Site F.

![Comparison of the relative affinity of AdpA~ch~ with different binding sites. Labeled probes S~A~, S~B~, S~C~, S~D~, S~E~, and S~F~ contained the fragment of Sites A--F as shown in **Figure [3A](#F3){ref-type="fig"}**, respectively. Probes S~A′~, S~B′~, S~C′~, S~D′~, S~E′~, and S~F′~ also contained the fragment of Sites A--F as shown in **Figure [3A](#F3){ref-type="fig"}**, respectively, but they are unlabeled. The amount of AdpA~ch~ protein used was 100 pM.](fmicb-09-00316-g004){#F4}

Promoter-Probe Assays of the AdpA~ch~-Binding Sites in the *scnRI*--*scnRII* Intergenic Region
----------------------------------------------------------------------------------------------

The binding sites of AdpA~ch~ in the *scnRI*--*scnRII* intergenic region were adjacent to either the *scnRI* or the *scnRII* start codon. This raised the possibility that this intergenic region might harbor a bidirectional promoter allowing AdpA~ch~ to regulate transcriptions of the divergently transcribed flanking genes, *scnRI* and *scnRII* (**Figure [2B](#F2){ref-type="fig"}**). To investigate the promoter activities of the two pathway-specific genes with each of the AdpA~ch~-binding sites, we used the promoter-probe plasmid pIJ8601 carrying the *xylE* gene, encoding catechol 2,3-dioxygenase, as the reporter. As shown in **Figure [5A](#F5){ref-type="fig"}**, the transcriptional profiles of *scnRI* were severely decreased when the AdpA~ch~-binding Site C and Site D were mutated. Conversely, its transcriptional activity was increased when Site A and Site B were mutated and remained almost unchanged when Site E and Site F were mutated. For the promoter activity of *scnRII*, we did not detect any consistent differences when Sites A, B, and C were mutated, but mutation in the Sites D and E resulted in a large decreases of up to 70 and 40%, respectively, compared to those of the wt. The mutation in Site F resulted in a statistically significant increase (**Figure [5B](#F5){ref-type="fig"}**). These findings indicated that expressions of *scnRI* and *scnRII* are both under the control of AdpA~ch~, which has a completely different regulatory ability (activation or inhibition) when binding to different binding sites.

![Promoter activities of *scnRI* **(A)** and *scnRII* **(B)** with the effect of mutations in the AdpA~ch~-binding sites. The strains were grown in YEME medium for 24 h, and catechol dioxygenase activity was calculated as the change of catechol quantity (mmol) per minute. Error bars correspond to the standard error of the mean of four culture replicates. ^∗^ Indicates significant differences between promoter mutants and promoter wt (*P* \< 0.05).](fmicb-09-00316-g005){#F5}

Effect of Mutated AdpA~ch~-Binding Sites On Natamycin Production *in Vivo*
--------------------------------------------------------------------------

There have been some reports where effects upon DNA-binding sites were found *in vitro* that failed to be exhibited *in vivo*. In order to test this possibility and reveal the function of the six AdpA~ch~-binding sites in natamycin biosynthesis *in vivo*, a series of mutants were constructed as described in Experimental procedures. As shown in **Figure [6A](#F6){ref-type="fig"}**, compared to the WT strain, the level of natamycin production in the R-mA (mutation in Site A) and R-mF (mutation in Site F) had increased by 21 and 25%, respectively. However, the constructed strains of R-mC (mutation in Site C), R-mD (mutation in Site D), and R-mE (mutation in Site E) showed up to 31, 42 and 15% reductions, respectively. The natamycin production of R-mB (mutation in Site B) mutant exhibited almost no change. This finding indicated that the AdpA~ch~-binding Sites A and F play negative roles for natamycin biosynthesis, while the functions of the Sites C, D, and E were positive. Quantitative real-time PCR (qRT-PCR) analysis showed that the promoting effect of site mutation on natamycin production was due to alteration of the pathway-specific genes at the transcriptional level (**Figure [6B](#F6){ref-type="fig"}**).

![**(A)** The effect of mutated AdpA~ch~-binding sites on the natamycin production *in vivo*. The strains were grown in YEME medium for 96 h. Vertical error bars correspond to the standard error of the mean of four replicated cultures. **(B)** Real-time RT-PCR analysis of the *scnRI* and *scnRII* transcript in the wt strain and mutated AdpA~ch~-binding sites strain. The expression level of *scnRI and scnRII* is presented relative to the wt sample from 24 h, which was arbitrarily assigned a value of 1. The transcription of *hrdB* was assayed as an internal control. Error bars were calculated by measuring the standard deviation among three replicates of each sample. ^∗^ Indicates significant differences between AdpA~ch~-binding site mutants and wt (*P* \< 0.05).](fmicb-09-00316-g006){#F6}

Discussion
==========

*Streptomyces* spp. have developed complicated mechanisms to adapt to altered circumstances ([@B31]; [@B39]). Among these mechanisms, the multiple levels of regulation in controlling the expression of the genes responsible for the formation of the secondary metabolism are drawing increased attention. In this study, we focused on the regulatory network of natamycin biosynthesis in *S. chattanoogensis* L10, an industrial strain for natamycin production. In our previous study, we determined that gamma-butyrolactones (GBLs) serve as quorum-sensing signaling molecules for activating natamycin production in *S. chattanoogensis* L10 ([@B6]), and ScnRII acts as a positive regulator by directly binding to the promoters of natamycin biosynthetic genes ([@B4]) where ScnRI acts as a positive regulator for the transcription of *scnRII* ([@B5]). However, the deletion of *scnRI* did not result in a complete halt of the transcription of *scnRII* (our unpublished data). This is quite different from the function of PimR in *S. natalensis* where the deletion of *pimR* almost completely destroys the transcription of *pimM* ([@B2]; [@B30]). As the regulation of antibiotic biosynthesis involves numerous transcription factors ([@B22]; [@B36]), participation of other regulator(s) is possible, in the regulation of *scnRII*.

With AdpA~ch~ being able to regulate the expression of both of the pathway-specific genes, *scnRI* and *scnRII*, it provides a possible explanation that there is a coordinate regulation in controlling expression of *scnRII* by AdpA~ch~ and ScnRI. This regulatory pattern may occur in following steps. Firstly, AdpA~ch~ binds to the *scnRI*--*scnRII* intergenic region and activates both transcription of *scnRI* and *scnRII*. Then ScnRI also binds to the *scnRI*--*scnRII* intergenic region which, in turn, promotes the transcriptional level of *scnRII*. However, these two genes were not completely controlled by AdpA~ch~. Trace expression of *scnRI* was observed in the *adpA~ch~* mutant, and then ScnRI would promote the transcription of *scnRII* ([@B5]). Notably, a certain amount of AdpA~ch~ is required for binding to the *scnRI*--*scnRII* intergenic region (∼50 pM). This is why we did not detect the shifted band with low concentration AdpA~ch~ (∼1 pM) in the binding reaction of our previous study ([@B5]).

In most cases, AdpA acts as an activator for the target genes, except for itself where it exhibits an autorepression ([@B14]). In this study, we concluded from promoter-probe assays *in vivo* that AdpA~ch~ could not only regulate both pathway-specific genes, but also displayed completely opposite regulatory abilities in control of them. The AdpA~ch~-binding Site C and Site D were involved in activating the transcription of *scnRI*, while AdpA~ch~ binding to Sites A and B resulted in repression. For the promoter activity of *scnRII*, mutation in the Site C and Site D resulted in a decrease of transcriptional profiles, while a mutation in the Site F led to a statistically significant increase. A similar phenotype was observed in *S. ansochromogenes* where transcription of *sanG* decreased when Site I and Site V were mutated but increased when other three AdpA-L-binding sites were mutated ([@B28]). However, when combinations of binding site mutations were carried out, the promoter activities were not in accordance with our predictions. For example, mutations in both Sites E and F reduced the transcriptional level of *scnRII* (data not shown). Based on the short distances between the AdpA~ch~-binding sites which are spread over the *scnRI*--*scnRII* intergenic region, there may be complicated interactions between different AdpA~ch~ dimmers to explain this.

With further analysis using competitive gel shift assays, we could conclude that AdpA~ch~ binds to Sites A--F with the following affinities: Site D \> Site C \> Site E \> Site A \> Site B \> Site F (**Figure [4](#F4){ref-type="fig"}**). These data are consistent with the footprinting assay where the regions of Site C and Site D were previously protected at a lower AdpA~ch~ protein concentration (**Figure [2A](#F2){ref-type="fig"}**). This gives a hint that the regulatory ability of AdpA~ch~ may occur in a growth phase-dependent manner. In the early stage, AdpA~ch~ firstly binds to the Site C and D to recruit RNA polymerase to the promoter and initiates the transcription of *scnRI* and *scnRII*. This in turn triggers natamycin production (**Figure [7](#F7){ref-type="fig"}**). When AdpA~ch~ is accumulated to a certain critical level, it will bind to other binding sites located near the TSS. A DNA loop may be formed via the interaction between different AdpA~ch~ dimers, thus preventing RNA polymerase from access to the promoter of the pathway-specific genes (**Figure [7](#F7){ref-type="fig"}**). Reduced transcription of the pathway-specific genes will result in a low rate of natamycin production.

![Proposed model of AdpA~ch~ regulation for *scnRI* and *scnRII* transcription. The AdpA~ch~-binding sites are spread over the *scnRI*--*scnRII* intergenic region, and the presumptive manner of AdpA~ch~-binding forms a dimmer. Stage 1: AdpA~ch~ binds to the Site C and Site D when the concentration of AdpA~ch~ is low in the early growth stage. Stage 2: When the concentration AdpA~ch~ reaches a high level, AdpA~ch~ binds to Site A, Site B, Site E, and Site F, most of which located downstream of the -35 sequences of the corresponding genes. A DNA loop may be formed via interaction between different AdpA~ch~ dimmers, thus preventing RNA polymerase from access to the promoter.](fmicb-09-00316-g007){#F7}

The discovery of this bidirectional regulation of AdpA~ch~ in the control of natamycin biosynthesis reveals an artful adaptive mechanism in microbial cells. Microorganisms produce molecules with antibiotic activity and expel them into the environment, presumably enhancing their ability to compete with their neighbors ([@B3]; [@B11]). However, most of these molecules are toxic to the producer ([@B20]; [@B23]). Mechanisms must exist to ensure that antibiotic production reaches a reasonable level. The proposed model of AdpA~ch~ in **Figure [7](#F7){ref-type="fig"}** may provide a fresh mechanistic insight into how *S. chattanoogensis* controls the production level of natamycin via AdpA~ch~. However, further work will be needed to prove the proposed model and the detailed mechanism of how AdpA~ch~ responds to the signal of natamycin. In all, the complicated regulatory network involving AdpA~ch~, ScnRI, and ScnRII helps advance our understanding of the molecular regulation mechanisms of antibiotic biosynthesis and provides an effective strategy to help improve yields in industrial strains.

###### 

Bacterial strains and plasmids used in this work.

  Strains/plasmids            Characteristics                                                           Reference
  --------------------------- ------------------------------------------------------------------------- ------------
  Strains                                                                                               
  *E. coli* TG1               General cloning host                                                      Novagen
  *E. coli* ET12567/pUZ8002   Methylation-deficient *E. coli* for conjugation with the helper plasmid   [@B19]
  *E. coli* BL21 (DE3)        A host for protein expression                                             Novagen
  *E. coli* BW25113/pIJ790    Strain used for PCR-targeted mutagenesis                                  [@B8]
  Wt                          *S. chattanoogensis* L10 wt; natamycin producer                           [@B4]
  *RI*-x                      wt with pIJ8601-*pRI*                                                     This study
  *RI*-mA-x                   wt with pIJ8601-*pRI-mA*                                                  This study
  *RI*-mB-x                   wt with pIJ8601-*pRI-mB*                                                  This study
  *RI*-mC-x                   wt with pIJ8601-*pRI-mC*                                                  This study
  *RI*-mD-x                   wt with pIJ8601-*pRI-mD*                                                  This study
  *RI*-mE-x                   wt with pIJ8601-*pRI-mE*                                                  This study
  *RI*-mF-x                   wt with pIJ8601-*pRI-mF*                                                  This study
  *RII*-x                     wt with pIJ8601-*pRII*                                                    This study
  *RII*-mA-x                  wt with pIJ8601-*pRII-mA*                                                 This study
  *RII*-mB-x                  wt with pIJ8601-*pRII-mB*                                                 This study
  *RII*-mC-x                  wt with pIJ8601-*pRII-mC*                                                 This study
  *RII*-mD-x                  wt with pIJ8601-*pRII-mD*                                                 This study
  *RII*-mE-x                  wt with pIJ8601-*pRII-mE*                                                 This study
  *RII*-mF-x                  wt with pIJ8601-*pRII-mF*                                                 This study
  R-mA                        wt with mutation in Site A                                                This study
  R-mB                        wt with mutation in Site B                                                This study
  R-mC                        wt with mutation in Site C                                                This study
  R-mD                        wt with mutation in Site D                                                This study
  R-mE                        wt with mutation in Site E                                                This study
  R-mF                        wt with mutation in Site F                                                This study
  Plasmids                                                                                              
  pTA2 vector                 General cloning vector                                                    TOYOBO
  p-*RI-RII*                  pTA2 containing the fragment of the *scnRI*--*scnRII* intergenic region   This study
  pIJ8601                     Streptomyces integrative shuttle vector with *xylE* reporter gene         This study
  pIJ8601-*pRI*               pIJ8601 with the promoter of *scnRI*                                      This study
  pIJ8601-*pRI-mA*            pIJ8601-*pRI* with mutation in Site A                                     This study
  pIJ8601-*pRI-mB*            pIJ8601-*pRI* with mutation in Site B                                     This study
  pIJ8601-*pRI-mC*            pIJ8601-*pRI* with mutation in Site C                                     This study
  pIJ8601-*pRI-mD*            pIJ8601-*pRI* with mutation in Site D                                     This study
  pIJ8601-*pRI-mE*            pIJ8601-*pRI* with mutation in Site E                                     This study
  pIJ8601-*pRI-mF*            pIJ8601-*pRI* with mutation in Site F                                     This study
  pIJ8601-*pRII*              pIJ8601 with the promoter of *scnRII*                                     This study
  pIJ8601-*pRII-mA*           pIJ8601-*pRII* with mutation in Site A                                    This study
  pIJ8601-*pRII-mB*           pIJ8601-*pRII* with mutation in Site B                                    This study
  pIJ8601-*pRII-mC*           pIJ8601-*pRII* with mutation in Site C                                    This study
  pIJ8601-*pRII-mD*           pIJ8601-*pRII* with mutation in Site D                                    This study
  pIJ8601-*pRII-mE*           pIJ8601-*pRII* with mutation in Site E                                    This study
  pIJ8601-*pRII-mF*           pIJ8601-*pRII* with mutation in Site F                                    This study

Materials and Methods {#s1}
=====================

Media, Plasmids, Strains, and Growth Conditions
-----------------------------------------------

All plasmids and bacterial strains used in this study are listed in **Table [1](#T1){ref-type="table"}**. General techniques for the manipulation of nucleic acids and bacterial growth were carried out according to the standard protocols as previously described ([@B15]). *Escherichia coli* DH5α was the general cloning host. Vectors used were pSET152, pIJ8660, pTA2. *S. chattanoogensis* L10 strains were grown at 28°C on YMG agar for sporulation and at 30°C in YEME medium (3 g/l yeast extract, 3 g/l malt extract, 5 g/l tryptone, 10 g/l glucose) for natamycin production.

Electrophoretic Mobility-Shift Assays (EMSAs)
---------------------------------------------

His-AdpA~ch~, histidine-tagged protein was purified from the soluble fractions of *E. coli* BL21 (DE3) harboring the plasmids pET32a-*adpA~ch~*, as previously described ([@B5]). The Bradford reagent (Bio-Rad) was used to determine the protein concentration. For probe preparation, all primers used in this study are listed in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}. The EMSA DNA probe RI--RII (517 bp) spanning the entire *scnRI*--*scnRII* intergenic region was amplified by PCR using primer pair RI--RII-F and RI--RII-R. The PCR product was then cloned into a pTA2-vector (TOYOBO) to generate the plasmid pT-*RI*--*RII*. The biotin-labeled probe RI--RII was made with 5′-biotin-labeled M13 universal primer pair using pT-*RI*--*RII* as a template by PCR amplification. The probes A (295 bp), B (281 bp), C (294 bp), D (282 bp), E (288 bp), F (284 bp), mA (295 bp), mB (281 bp), mC (294 bp), mD (282 bp), mE (288 bp), and mF (284 bp) were prepared following the above-mentioned method. In the EMSAs assay, 1 ng of the probe was incubated with varying quantities of AdpA~ch~, at 25°C for 30 min in the buffer (20 mM Tris, pH 7.5, 5% glycerol, 0.01% BSA, 50 μg ml^-1^ sheared sperm DNA). For the competition assay, 100 times of excessive un-labeled probes and non-specific DNA were added to the reaction buffer, respectively. Reactions were displayed on 5% acrylamide gels for separation in 0.5× TBE buffer. EMSA gels were then electro-blotted onto the nylon membrane and UV-fixed by UV crosslinker. Labeled DNA was detected with streptavidin-HRP and BeyoECL plus (Beyotime, China) as described by the manufacturer.

DNase I Footprinting Assay
--------------------------

DNase I footprinting assay was performed as previously described ([@B21]). Firstly, AdpA~ch~ protein was ultra-filtered with YM-10 (Millipore) for 10 kD cut-off and eluted in 20 mM Tris buffer, pH 7.5. Then, FAM-labeled probe was amplified using 5′-(6-FAM)-labeled M13 universal primers from plasmid pT-*RI*-*RII*, followed by gel recovery. About 50 ng of fluorescently labeled probe was added to the reaction mixture to a final volume of 50 μl. After binding of the AdpA~ch~ protein to 5′-(6-FAM)-labeled probe (30°c, 30 min), 0.01 U of DNase I (Promega) was added for 1 min at 30°C, followed with equal volume of 100 mM EDTA to stop the reactions and extracted by phenol/chloroform. After precipitation with 40 μg of glycogen, 0.75 M ammonium acetate (NH~4~Ac), and ethanol, the digested DNA mixture was loaded into ABI 3130 DNA sequencer with Liz-500 DNA marker (MCLAB). DNA sequencing ladder was prepared according to Thermo Sequenase Dye Primer Manual Cycle Sequencing Kit (USB).

Alterations of the Consensus Sequence for AdpA~ch~-Binding Sites
----------------------------------------------------------------

The consensus sequence of AdpA~ch~-binding sites A--F was replaced by the sequence of EcoRV restriction sequence sites using overlapping primers (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). The PCR product was then cloned into a pTA2-vector (TOYOBO). The resulted plasmids were used as template for PCR to amplify mutated probes using 5′-biotin-labeled M13 universal primers, and the binding ability was measured by EMSAs.

Construction and Analysis of Transcriptional Fusions to the *xylE* Reporter Gene
--------------------------------------------------------------------------------

For *xylE* fusions, the *xylE* gene was PCR amplified with the primers *xylE*-F and *xylE*-R. This fragment was digested with *Nde*I and *Not*I, and introduced into the likewise-digested pIJ8660 ([@B32]) to construct pIJ8601. To probe *scnRIp* and *scnRIIp* activities with the mutation of AdpA~ch~-binding sites, the wt and mutated promoter regions were amplified by PCR using upstream primers carrying a BamHI site listed in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}. These promoter fragments were cloned into BamHI-cut pIJ8601 and transferred by conjugation into *S. chattanoogensis* L10. Plasmid-containing strains were grown on YEME medium for 24 h. Cell pellets from 1 ml culture samples were kept on ice and measured immediately. Assays of catechol 2,3-dioxygenase were performed as previously described ([@B15]).

Mutational Analysis of the AdpA~ch~-Binding Sites On Natamycin Biosynthesis
---------------------------------------------------------------------------

The 1.8 kb DNA fragment containing the sequence of *scnRI*--*scnRII* intergenic region was amplified by PCR using primers scnRI-F and scnRII-R. The resulted 1.8 kb sequence was used as template to amplify the DNA fragment for construction of mutated AdpA~ch~-binding sites *in vivo* using overlapping primers (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}), then PCR product was purified and ligated into pKC1139. The resulting plasmids containing DNA fragment of mutated sites was conjugated by *E. coli* ET12567/pUZ8002 into *S. chattanoogensis* L10. The mutants were selected by replica plating for apramycin-sensitive colonies and they were used as template for PCR with primer pairs RI-RII-F and RI-RII-R. The amplified sequences were digested with EcoRV to confirm the mutants.

Determination of Natamycin Production by HPLC Analysis
------------------------------------------------------

Natamycin production was confirmed by HPLC analysis with the Agilent 1100 HPLC system. HC-C~18~ column (5 μm, 4.6 by 250 mm) was used with UV detector set at 303 nm. Mobile phase and gradient elution process were as described previously ([@B4]).
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